Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization

Industry Watch   [to 6 January 2018]

:: Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization

BEIJING, Dec. 22, 2017 /PRNewswire/ — Sinovac Biotech Ltd. announced today that it has received a positive decision from the World Health Organization (“WHO”) on the acceptability, in principle, of its Healive, a hepatitis A vaccine product, for purchase by United Nations (“UN”) agencies. The Company’s Healive product was assessed according to the WHO Prequalification Procedure.

Mr. Weidong Yin, Chairman, President and CEO of the Company, commented that “I am very pleased that Healive has passed the assessment under WHO Prequalification procedures. This is an important milestone for Sinovac which we expect will provide opportunities to supply this vaccine to respective UN agencies as well as accelerate the regulatory approval process for this vaccine in international countries outside China.”…